Publications (2)0 Total impact
[show abstract] [hide abstract]
ABSTRACT: To investigate the effect and possible mechanism of curcumin to induce apoptosis in ovarian cancer resistant cell lines COC1/DDP. COC1/DDP cells were treated with different concentration of curcumin, with or without the combination of chemotherapy drugs cisplatin (DDP) and paclitaxel (PIX) for 48 hours. The growth inhibition rates of COC1/DDP cells were studied by MTT method, and the apoptotic ratios were measured with flow cytometry. The expression of phosphoinositide 3-kinase catalytic subunit (PI3KCA) mRNA was studied by RT-PCR in curcumin treated cells, DDP treated cells and their combination treated cells. After the treatment of different concentration of curcumin for 48 hours, the growth inhibition rates and the apoptotic rate of COC1/DDP cells were gradually increased accordingly with increasing curcumin concentration. Furthurmore, curcumin in combination with chemotherapy drug obtained higher inhibition rate and apoptosis rate than single chemotherapy drug did (P < 0.05). The expression of PI3KCA mRNA of COC1/DDP cells treated with curcumin combined DDP was much lower than that treated only with DDP (P < 0.05). Curcumin can increase the apoptotic rate of COC1/DDP cells, so has synergistic effect on with chemotherapy drugs on the induction of cell apoptosis. Its possible mechanism may be related to the down-regulation of PI3KCA.Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 05/2012; 43(3):335-9.
Article: [Expression of SATB1 and BRMS1 in ovarian serous adenocarcinoma and its relationship with clinieopathological features].[show abstract] [hide abstract]
ABSTRACT: To study the expression and clinical significance of SATB1, BRMS1 in Ovarian serous adenocarcinoma. Immanohistochemistrical SP method was used to detect the expression of SATB1, BRMS1 in 11 cases of normal ovarian tissue and 11 cases of benign ovarian tumor and 10 cases of ovarian borderline tumor and 53 cases ovarian serous adenocarcinoma. The expression of SATB1 in ovarian serous adenocarcinoma (86.8%) was significantly higher than those of normal ovarian tissues (0) and benign ovarian tumor tissues (36.4%), P < 0.05, and there was no difference between ovarian borderline tumor (70%) and ovarian serous adenocarcinoma, P > 0.05. The expression of BRMS1 in ovarian serous adenocarcinoma (28. 3%) was significantly lower than those in normal ovarian tissues (100%) and benign ovarian tumor tissues (81.8%), P < 0. 05, and there was no difference between ovarian borderline tumor (60%) and ovarian serous adenocarcinoma, P > 0.05. The inverse correlation between the expression of SATB1 and BRMS1 was observed (r = -0.387, P < 0.05). The expression of SATB1 was correlated with surgical stage and lymph node metastasis (P < 0.05), BRMS1 was correlated with surgical stage, lymph node metastasis and tumor size (P < 0.05); SATB1 and BRMS1 had no correlation with the patients whether menopause or not, histopathological grading, ascites (P > 0.05). SATB1 and BRMS1 might play an important role in the development and lymph node metastasis of ovarian cancer.Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 01/2011; 42(1):82-5, 105.